AUL
NBIX icon

AlphaGrep UK Ltd’s Neurocrine Biosciences NBIX Stock Holding History

AlphaGrep UK Ltd’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$560K Buy
4,252
+91
+2% +$12.1K 0.16% 194
2025
Q4 		$590K Buy
+4,161
New +$603K 0.2% 157

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AlphaGrep UK Ltd's NBIX Position: Q1 2026 in Review

AlphaGrep UK Ltd increased its Neurocrine Biosciences (NBIX) stake by 2.2% in Q1 2026, buying an estimated $12.1K and bringing the position to 4,252 shares worth $560K. The position accounts for 0.16% of the portfolio, ranked #194.

AlphaGrep UK Ltd first reported a position in NBIX in Q4 2025 and has held it in 2 quarters since. The position peaked at $590K in Q4 2025. 697 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • AlphaGrep UK Ltd held 4,252 shares of Neurocrine Biosciences worth $560K as of Q1 2026.
  • AlphaGrep UK Ltd bought 91 Neurocrine Biosciences shares in Q1 2026, an estimated $12.1K.
  • Neurocrine Biosciences made up 0.16% of AlphaGrep UK Ltd's portfolio in Q1 2026, its #194 holding.
  • AlphaGrep UK Ltd first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 2 quarters since.
  • AlphaGrep UK Ltd's Neurocrine Biosciences position peaked at $590K in Q4 2025.
  • 697 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on AlphaGrep UK Ltd's 13F filing for Q1 2026, filed 13 Aug 2026.